Founded with a mission to revolutionize osteoarthritis treatment, Sarcio focuses on regenerative cartilage cell therapy. The company's vision is to alleviate the debilitating effects of osteoarthritis by restoring hyaline cartilage and reducing inflammation through evidence-based induced pluripotent stem cell (iPSC) derived therapies. Sarcio is also developing an off-the-shelf, injectable regenerative therapy aimed at delaying or preventing the need for joint replacement, targeting a market of patients seeking advanced, non-invasive treatment options.
Sarcio's team includes leading experts in stem cell research and regenerative medicine, backed by notable investors in the biotech sector. The company has achieved significant milestones in preclinical trials, demonstrating the efficacy of its iPSC-derived hyaline cartilage cell therapy. Sarcio's innovative approach has the potential to transform osteoarthritis treatment, offering patients a promising alternative to traditional joint replacement surgeries.
